产品
编 号：F128684
分子式：C39H42N4O9S
分子量：742.84
分子式：C39H42N4O9S
分子量：742.84
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1345728-04-2
产品详情
生物活性：
Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA). Naldemedine tosylate shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine can be used in opioid-induced constipation (OIC) research. Naldemedine tosylate is predicted to bind to 3CLpro encoded by SARS-CoV2 genome.
体内研究：
Naldemedine tosylate (oral gavage; 0.03-10 mg/kg; once) represses the opioid-induced inhibition of small intestinal transit in rats.Animal Model:6-week-old Wistar and SD male rats
Dosage:0.03-10 mg/kg
Administration:Oral gavage; 0.03-10 mg/kg; once
Result:Repressed the subcutaneous inhibition of small intestinal transit in rats with an ED50 of 0.03 mg/kg
Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA). Naldemedine tosylate shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine can be used in opioid-induced constipation (OIC) research. Naldemedine tosylate is predicted to bind to 3CLpro encoded by SARS-CoV2 genome.
体内研究：
Naldemedine tosylate (oral gavage; 0.03-10 mg/kg; once) represses the opioid-induced inhibition of small intestinal transit in rats.Animal Model:6-week-old Wistar and SD male rats
Dosage:0.03-10 mg/kg
Administration:Oral gavage; 0.03-10 mg/kg; once
Result:Repressed the subcutaneous inhibition of small intestinal transit in rats with an ED50 of 0.03 mg/kg
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备